Order Article Reprints

Mattei JC, Bouvier-Labit C, Barets D, Macagno N, Chocry M, Chibon F, Morando P, Rochwerger RA, Duffaud F, Olschwang S, et al. Pan Aurora Kinase Inhibitor: A Promising Targeted-Therapy in Dedifferentiated Liposarcomas With Differential Efficiency Depending on Sarcoma Molecular Profile. Cancers. 2020; 12(3):583. https://doi.org/10.3390/cancers12030583

Mattei, Jean Camille, Corinne Bouvier-Labit, Doriane Barets, Nicolas Macagno, Mathieu Chocry, Frédéric Chibon, Philippe Morando, Richard Alexandre Rochwerger, Florence Duffaud, Sylviane Olschwang, and et al. 2020. "Pan Aurora Kinase Inhibitor: A Promising Targeted-Therapy in Dedifferentiated Liposarcomas With Differential Efficiency Depending on Sarcoma Molecular Profile" Cancers 12, no. 3: 583. https://doi.org/10.3390/cancers12030583

Mattei, J. C., Bouvier-Labit, C., Barets, D., Macagno, N., Chocry, M., Chibon, F., Morando, P., Rochwerger, R. A., Duffaud, F., Olschwang, S., Salas, S., & Jiguet-Jiglaire, C. (2020). Pan Aurora Kinase Inhibitor: A Promising Targeted-Therapy in Dedifferentiated Liposarcomas With Differential Efficiency Depending on Sarcoma Molecular Profile. Cancers, 12(3), 583. https://doi.org/10.3390/cancers12030583